SUMATRIPTAN/NAPROXEN (Suvexx)

Clinical Indication

Acute treatment of the headache phase of migraine attackes with or without aura in adults where treatment with a monoentity product has been insufficient

Date of classification

June 2025

Grey

Not yet reviewed drugs with no traffic light recommendation so not yet approved for use in LLR.

  • New medicines, devices, appliances.
  • New indication of existing medicine.
  • New NICE TA which has not been reviewed.
  • Not been requested for review by either TAS/LPT MMC.